JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer by Yi Fang Lee et al.
RESEARCH ARTICLE Open Access
JMJD6 is a driver of cellular proliferation and
motility and a marker of poor prognosis in
breast cancer
Yi Fang Lee1, Lance David Miller2, Xiu Bin Chan1, Michael A Black6, Brendan Pang3, Chee Wee Ong3,
Manuel Salto-Tellez4,5, Edison T Liu1,7 and Kartiki V Desai8*
Abstract
Introduction: We developed an analytic strategy that correlates gene expression and clinical outcomes as a means
to identify novel candidate oncogenes operative in breast cancer. This analysis, followed by functional
characterization, resulted in the identification of Jumonji Domain Containing 6 (JMJD6) protein as a novel driver of
oncogenic properties in breast cancer.
Methods: Through microarray informatics, Cox proportional hazards regression was used to analyze the correlation
between gene expression and distant metastasis-free survival (DMFS) of patients in 14 independent breast cancer
cohorts. JMJD6 emerged as a top candidate gene robustly associated with poor patient survival.
Immunohistochemistry, siRNA-mediated silencing, and forced overexpression of JMJD6 in cell-based assays
elucidated molecular mechanisms of JMJD6 action in breast cancer progression and shed light on the clinical
breast cancer subtypes relevant to JMJD6 action.
Results: JMJD6 was expressed at highest levels in tumors associated with worse outcomes, including ER- and basal-like,
Claudin-low, Her2-enriched, and ER+ Luminal B tumors. High nuclear JMJD6 protein was associated with ER negativity,
advanced grade, and poor differentiation in tissue microarrays. Separation of ER+/LN- patients that received endocrine
monotherapy indicated that JMJD6 is predictive of poor outcome in treatment-specific subgroups. In breast cancer cell
lines, loss of JMJD6 consistently resulted in suppressed proliferation but not apoptosis, whereas forced stable
overexpression increased growth. In addition, knockdown of JMJD6 in invasive cell lines, such as MDA-MB231,
decreased motility and invasion, whereas overexpression in MCF-7 cells slightly promoted motility but did not confer
invasive growth. Microarray analysis showed that the most significant transcriptional changes occurred in cell-
proliferation genes and genes of the TGF-b tumor-suppressor pathway. High proliferation was characterized by
constitutively high cyclin E protein levels. The inverse relation of JMJD6 expression with TGF-b2 could be extrapolated to
the breast cancer cohorts, suggesting that JMJD6 may affect similar pathways in primary breast cancer.
Conclusions: JMJD6 is a novel biomarker of tumor aggressiveness with functional implications in breast cancer
growth and migration.
Introduction
In breast cancer, resistance to standard-of-care systemic
adjuvant treatments such as endocrine and chemothera-
pies remains a major health burden and prompts the
need for novel therapeutic targets for patients with
advanced, unresponsive, or relapsed disease. We pre-
viously used gene-expression profiles of breast tumors to
identify extracellular/secretory proteins and cell surface-
receptor genes whose high expression levels associate
with poor clinical end points. For example, we recently
identified serine protease inhibitor Kazal-type 1 (SPINK1)
as an important therapeutic target in breast cancer by
using a combined genotype and phenotype screening
approach. We found that inhibition of SPINK1 by
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neutralizing antibodies curtailed multiple aggressive
properties, including cell survival, invasiveness, and che-
moresistance [1]. A second candidate identified in the
same study was the phosphatidylserine receptor (PTDSR).
Formerly, PTDSR was thought to be a cell-surface
protein that facilitates recruitment of phagocytic cells to
sites of apoptosis. Antibodies against PTDSR and
annexin V have been used in combination to estimate
apoptosis [2]. Mouse knockouts of PTDSR showed early
postnatal lethality and had growth retardation and mul-
tiple developmental abnormalities due to insufficient dif-
ferentiation during embryogenesis; however, no defect in
apoptotic clearance of cells was evident [3]. By genera-
tion of deletion mutants and immune localization, Cui
et al. [4] demonstrated that PTDSR is a nuclear protein,
with five nuclear localization signals scattered through-
out its sequence. Later, PTDSR was renamed Jumonji
domain containing 6 (JMJD6) based on the presence of
its JMJC domain with bifunctional histone arginine
demethylation and lysyl oxidase activity [4-6]. JMJD6 is
homologous to the hypoxia-inducible factor (HIF) aspar-
aginyl-hydroxylase, suggesting a function in cellular
response to hypoxia. In addition, JMJD6 protein was
recently shown to interact with splicing factor U2AF65;
however, very few splicing events in a limited number of
genes were attributable to JMJD6 expression [6]. In
endothelial cells, alternate splicing of VEGF receptor
(Flt1) by U2AF65 promoted endothelial cell migration,
and siRNA-mediated knockdown of JMJD6 in endothe-
lial cells led to decreased migration [7]. Based on X-ray
crystallographic data, it was predicted and shown that
apart from its enzymatic activity, JMJD6 protein bound
single-stranded RNA [8]. These diverse findings predict
a range of versatile functions for JMJD6, at the tran-
scriptional, splicing, posttranscriptional, and biochemical
levels. However, very little is known about the role of
JMJD6 in cancer and the molecular pathways that may
impinge on disease initiation and prognosis.
Because our in silico analysis demonstrated a robust
positive association between JMJD6 expression and
breast cancer recurrence, we investigated its phenotypic
and molecular effects in breast cancer cells. We report
herein that perturbation of JMJD6 expression modulates
cell proliferation and cell scattering and motility: pheno-
types associated with cancer metastasis. Furthermore,
our findings suggest that these cellular phenotypes may
be elicited by JMJD6-mediated suppression of trans-
forming growth factor-beta 2 (TGF-b2) and/or activa-
tion of proteins that potentiate cell division in a cell
type-specific manner. These in vitro mechanistic find-
ings are consistent with the clinical observations that
JMJD6 expression correlates positively with proliferation
index and high histologic grade but inversely with TGF-
b2 expression. Together, these data implicate JMJD6
function in breast tumor progression and suggest a diag-
nostic role for JMJD6 in predicting patient outcomes.
Materials and methods
Breast cancer clinical datasets
Tumor-expression profiles were obtained with approval
from and in accordance with the policies of the institu-
tional review boards of the respective institutions. An
integrated “Super Cohort” (SC) of 15 individual Affyme-
trix array datasets comprising 2,116 breast cancer
patients was used in this analysis. These datasets were
previously described in detail in Soon et al. [1]. These
cohorts were accessible from public databases, Gene
Expression Omnibus (National Center for Biotechnology
Information, Bethesda, MD, USA), ArrayExpress (Eur-
opean Bioinformatics Institute, Hinxton, UK), and caAr-
ray (National Cancer Institute, NIH, Atlanta, GA, USA).
Appropriate permission has been granted for the use of
the datasets and corresponding de-identified clinical
data. A summary of the clinical dataset details and lit-
erature references can be found in Additional file 1,
Table S1. Initial discovery and meta-analysis was per-
formed on a subset of this Super Cohort.
All raw data (CEL files) were preprocessed and nor-
malized by using the R software package [9], and library
files provided via the Bioconductor [10]. Raw data were
MAS5.0 normalized on a per-cohort basis by using the
justMAS function in the simpleaffy library from Biocon-
ductor (no background correction, target intensity of
600). Cross-cohort batch effects were corrected by using
the COMBAT empirical Bayes method [11]. Normalized
JMJD6 probesets, 212722_s_at and 212723_at, were
averaged for the analysis of data from Affymetrix U133
arrays, and JMJD6 probe, AB011157, was used for the
analysis of the Agilent array dataset (that is, the NKI
dataset). Of 2,116 array profiles in the Super Cohort,
1,954 patient cases are annotated with distant metasta-
sis-free survival (DMFS) time and event information.
Clinical survival analysis and expression in subtypes
Distant metastasis-free survival (DMFS) was used as the
clinical end point of interest. A DMFS event was defined
as metastatic recurrence to a distant organ site or in a
limited number of cases, as death owing to progressive
breast cancer. Cox proportional hazard regression analy-
sis of JMJD6 expression with DMFS data (Time and
Event) was performed in individual patient datasets and
in the Super Cohort. Clinical subtype analysis was per-
formed by using the Super Cohort. Intrinsic subtypes
were assigned via the PAM50 algorithm of Parker et al.
[12], by using the code provided by the authors at UNC
Microarray Database [13]. Gene data were matched by
symbol and median centered, and Spearman correlation
was used to assign samples to the nearest PAM50
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centroid. Claudin-Low subtypes were assigned based on
the method described by Prat et al. [14], by using the
microarray data (GSE18229) and information provided
by the authors at UNC Microarray Database [13]. Clau-
din-Low and Normal centroids were generated, and
samples were assigned to one or the other class based
on euclidean distance to the class centroid. The PAM50
and Claudin-Low subtype information was then com-
bined with the PAM50 subtype used, unless a sample
had been classified as Claudin-Low, in which case, the
Claudin-Low assignment would take precedence.
Distribution of JMJD6 expression in various breast
cancer subtypes was analyzed with the Kruskal-Wallis
one-way analysis of variance (ANOVA) on ranks and
multiple pairwise comparisons with the Dunn method
by using Sigma Plot. Statistical significance of differen-
tial JMJD6 expression in ER-positive versus ER-negative
tumors was analyzed by using the Mann-Whitney Rank
Sum Test. In Kaplan-Meier and CoxPH survival analysis
of JMJD6 expression cohorts in the clinical subtypes, the
patients were separated by median expression across the
Super Cohort into high and low JMJD6-expression
groups. Kaplan-Meier survival analysis also was per-
formed on patient groups ranked by quartile expression
within each clinical subtype. All survival analyses were
performed by using Sigma Plot [15].
Immunohistochemistry
Tissue microarray (TMA) blocks containing cores from
98 breast cancer patients were constructed, as described
previously, under institutional ethics committee approval
with consent for the tissue microarray program (NUS-
IRB 05-017) [1,16,17] and used for the analysis. Anti-
JMJD6 monoclonal antibody (Santa Cruz, Santa Cruz,
CA, USA: Sc-28348) was used at a dilution of 1:50 along
with antigen retrieval by heat and Tris-EDTA (pH 9.1).
Automated IHC scoring was performed with the Ariol
SL-50 image analysis system (Applied Imaging, Santa
Clara, CA, USA). Positivity of JMJD6 nuclear expression
was defined as nuclear-staining intensity and percentage
coverage scores ≥25%. Odds-ratio analysis was per-
formed on JMJD6-positive expression and clinicopatho-
logic features of the tumors by using PASW Statistics
18 [18].
Cell lines
All cell lines were obtained from American Type Cul-
ture Collection (ATCC) and maintained in growth
media, at 37°C with 5% CO2. The growth medium for
MCF-7, CAMA-1, and BT-549 was Dulbecco Modified
Eagle Medium (DMEM), with 10% fetal bovine serum
(FBS); and for MDA-MB231 and T47D, it was RPMI-
1640, with 10% FBS.
Cloning and expression of JMJD6
JMJD6 (NM_001081461.1) (J1) was amplified by using
MCF-7 mRNA (forward primer: 5’CCCAAGCTTAT-
GAACCACAAGAGCAAGAAG3’; reverse primer: 5’
GCTCTAGATCACCTGGAGGAGCTGCG 3’), followed
by reamplification with forward primer: 5’ GAGGTAC-
CATGAACCACAAGAGCA 3’ and reverse primer: 5’
CGCTCGAGTGGGGGTGAGCCCGGCCT 3’ and
ligated into TOPO pCR2.1 vector. All clones were
sequence verified. JMJD6 was cloned from TOPO vec-
tors into a gateway entry vector pENTR3C (Invitrogen)
and then recombined into the lentivirus vector
pLenti6.2/V5-DEST (Invitrogen), pLenti4/V5-Dest (Invi-
trogen), and pcDNA3.1/V5-Dest (Invitrogen) by LR
recombination, according to the manufacturer’s proto-
col. For lentiviral clones, pLenti6.2/V5-DEST or
pLenti4/V5-Dest was co-transfected with packaging vec-
tors (Invitrogen) into 293 FT cells, and the supernatant
was harvested approximately 48 hours for packaged len-
tivirus. For infection of MCF-7 cells, the cells were pla-
ted at 50% confluence and incubated with 20 μl to 30 μl
of the concentrated virus and 8 μg/ml of hexamethrine
bromide (Polybrene) for 24 hours at 37°C. The cells
were replated and cultured with Zeocin (Invitrogen) to
obtain several clones (MCF7-J1-OE). The pcDNA3.1
vector was used to generate JMJD6 expression clones by
transfection by using Lipofectamine 2000 (Invitrogen)
into MDA-MB231, T47D, and CAMA cell lines. Stable
clones were selected with gentamycin (Gibco).
Knockdown of JMJD6 gene
SiRNA was reverse transfected (by using manufacturer’s
protocol) by using Lipofectamine 2000 (Invitrogen) into
the cell lines. At 48 hours after transfection, the cells
were reconstituted in fresh media for experimental
assays. JMJD6 siRNAs used were as follows: siRNA A
(Ambion: 111915)- gcuauggugaacacccuaatt; siRNA B
(Dharmacon: D-010363-01)- gaacugggauucacaucga;
siRNA C (Dharmacon: D-010363-02)- ggauaacgauggcua-
cuca; and siRNA D (Dharmacon: D- 010363-05)-
ggacccggcacaacuacua. A nontargeting scrambled siRNA
served as a negative control (Ambion: 4635).
Cell-based assays
For proliferation assay, cells were plated in 96-well
plates at a density of 5,000 cells per well. Cell prolifera-
tion was measured by using WST-1 (Roche) every
24 hours over a 4- to 5-consecutive-day period, accord-
ing to manufacturer’s protocol. For detecting apoptosis,
cells were transfected in a 96-well plate with siRNAs
and assessed for apoptotic markers after 48 hours. In
brief, the cells were fixed with paraformaldehyde, and
cells were permeabilized with Triton-X 100. Fixed cells
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were probed with active PARP (BD, 552596) antibody,
and the primary antibodies were detected by a second-
ary antibody conjugated to fluors Alexa 488 (BD,
A21121). ArrayScan VTI (Cellomics) was used to detect
immunofluorescence, and the baseline threshold was set
by using cells stained with secondary antibody alone in
the absence of the primary antibody.
Scatter assay
Cells were plated in six-well plates at a density of 300
cells per well and grown in DMEM with 10% FBS. Fifteen
fields of colonies per cell type were captured on day 7 of
growth and blindly scored for three categories of scatter-
ing (compact, loose, and scatter) by two random indivi-
duals from six people. An average score was calculated
for each colony, and the percentage of colonies for each
category of scattering was plotted [19].
Wound-healing assay
Cells were plated in culture inserts (Ibidi) with approxi-
mately 500 μM gap. After 2 days (confluent cells), the
inserts were removed, and fresh medium with 5 μg/ml of
mitomycin C (Calbiochem, 47589) was added. The dis-
tances moved by the cells across the gap were measured at
24 hours and calculated as a ratio over the initial distance
at 0 hours, and these data were further normalized to the
ratio of distance in Vec control.
Invasion and migration assay
In vitro migration and invasion of the cells were assessed
by using Falcon FluoroBlok 24-Multiwell inserts with
8-μm pores (BD Biosciences). For invasion assays, the
inserts were coated with 20 μg of Matrigel in 80 μl of
serum-free media. Cell suspension (200 μl) in serum-free
media was loaded into each transwell insert, and 750 μl
of medium with 10% FBS was provided in the lower
chamber; 4 × 104 MDA-MB231/BT-549 cells were loaded
in each transwell. The assay was done for 18 hours for
migration and 24 hours for invasion. The cells that had
migrated or invaded through the inserts were fixed with
3.7% formaldehyde and stained with propidium iodide,
2 μg/ml (Calbiochem), for 30 minutes, washed with PBS,
and counted for 10 fields by using the Target Activation
Bioapplication on an ArrayScan VTI (Cellomics). Assay
results for siRNA-treated MDA-MB231 cells were nor-
malized to fold change observed in proliferation at Day 2
and then calculated as a ratio to the Sc siRNA control.
Microarray data analysis
MCF-7 J1 clones were harvested for RNA isolation at
80% confluence. For siRNA-mediated knockdown of
JMJD6 in MCF-7 and MDA-MB231, the cells were har-
vested for RNA isolation immediately, 48 hours after
transfection. Cells were washed twice with PBS and har-
vested by trypsinization. RNA was extracted by Trizol
(Invitrogen) according to manufacturer’s protocol. Three
biological replicates of MCF-7 J1 clones and two inde-
pendent siRNA-transfection replicates were used for the
microarray hybridization. Processing of samples for
hybridization on Affymetrix U133 Plus 2.0 was done
according to manufacturer’s protocol. The microarray
data were uploaded to Gene Expression Omnibus
(accession number, GSE31782). Raw data were MAS5-
normalized and log transformed by using Genespring
GX11.5. To extract differential gene expression, Gene-
Spring GX 11.5 was used to perform two-way ANOVA
for siRNA-specific changes in MCF-7 and MDA-
MB231. The list of significantly differential genes (P <
0.05) was further filtered for genes with at least 1.5-fold
change in expression in at least one of the siRNA treat-
ments for either MCF-7 or MDA-MB231. For MCF-7
J1-OE clones, one-way ANOVA was performed to
extract differential gene expression in the overexpression
clones as compared with the Vec. Only genes that dif-
fered in their expression by 1.5-fold in at least one of
the clones were selected for further analysis. Genes that
overlapped in both siRNA treatment and in J1 clones
and those that were regulated in the opposite direction
were selected for Ingenuity Pathway Analysis (IPA) [20].
Hierarchical clustering by average linkage and visualiza-
tion of the clusters was performed by using Cluster and
Treeview, respectively [21,22].
To extract differential gene expression specific to
MDA-MB231, GeneSpring GX11.5 was used to per-
form one-way ANOVA in MDA-MB231 and MCF-7
independently. The list of significant genes that were
differentially expressed (1.5-fold; P < 0.05) was fil-
tered. Probesets unique to MDA-MB231 that were
absent in MCF-7 lists were extracted for IPA func-
tional analysis.
Real-time PCR
Total RNA was reverse transcribed by using Maxima
reverse transcriptase mix (Fermentas). Real-time PCR
was performed by using SYBR-Green PCR Mix (Fer-
mentas) and run on CFX384 Real Time PCR Detection
System (Biorad). Ct values were generated by using CFX
manager software (Biorad). The primers used are listed
in the Additional file 2, Table S2.
Conditioned media
To obtain conditioned media, plated cells were incu-
bated with serum-free media for 24 hours before collec-
tion. The media were spun down to remove any cell
debris and then concentrated ×60 to 80 by using Ami-
con Ultra centrifugation filter (Millipore).
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Immunoblot analysis
Whole-cell lysates were prepared by using RIPA buffer for
all antibodies, except TGF-bs, detected in conditioned
media. Protein concentration was quantified by using
Protein Assay reagent (Biorad) with BSA standards. Equal
amounts of total protein lysates (20 to 40 μg) were ana-
lyzed on an SDS-PAGE gel and transferred to PVDF
membrane (GE Healthcare and Millipore). Antibodies
against JMJD6 (Abcam, ab10526), b-actin (Sigma, A5441),
V5 tag (Invitrogen, R960-25), E-cadherin (Cell Signaling,
4065), vimentin (BD Pharmingen, 550513), TGF-b2
(Abcam, ab36495), phosphorylated SMAD2 (Cell Signal-
ing, 3108 and 3104), phosphorylated SMAD3 (Cell Signal-
ing, 4520), SMAD2/3 (Cell Signaling, 3102), cyclin D1
(ab24249), cyclin E1 (Abcam, ab3927), and cyclin E2
(Abcam, ab40890) were used to probe for the protein on
the membrane. The detection was done by using HRP-
conjugated antibodies (Santa Cruz) and ECL or ECL Plus
reagents (Amersham Biosciences). Reactive proteins were
identified with autoradiography.
TGF-b2 neutralization and Smad phosphorylation assays
Cells were plated in 96-well plates at a density of 5,000
cells per well and changed to fresh media with either 5
ng/ml of recombinant human (rh) TGF-b2 (R&D Sys-
tems, 302-B2) or BSA the next day. Cell-viability mea-
surement was taken on the first day of TGF-b2 or
BSA treatment and 3 days later by using WST-1 assay.
To inhibit TGF-b2 action, cells were plated in 96-well
plates at a density of 5,000 cells per well. After
24 hours, they were exposed to 10 μM SB431542
(Sigma-Aldrich, S4317) or DMSO (as vehicle control)
before transfection with JMJD6 siRNA. The cells were
changed to fresh media 48 hours after transfection, con-
taining 10 μM SB431542 or DMSO. Cell viability was
determined on the first day of SB431542 or DMSO
treatment and 3 days later by WST-1 assay. For assess-
ment of SMAD2 phosphorylation, cells were plated at
approximately 50% confluence in six-well plates for
24 hours. The cells were pretreated for 2 hours with
SB431542 (Sigma-Aldrich, S4317) or DMSO, before
addition of 5 ng/ml of rhTGF-b2 (R&D Systems, 302-
B2). Protein lysates were harvested 1 hour after rhTGF-
b2 treatment for immunoblot analysis.
Clinical correlation between TGF-b2 and JMJD6
The super-cohort dataset was used to assess correlation,
if any, between JMJD6 and TGF-b2 expression. TGF-b2
probesets, 209908_s_at, 220407_s_at, 209909_s_at, and
220406_at, were averaged for the clinical microarray
data analysis. Correlation of JMJD6 expression and
TGF-b2 expression was performed by using the Pearson
correlation test on PASW Statistics 18 [18].
Results
JMJD6 transcript levels correlate with poor prognosis in
breast cancer
To discover novel oncogenes associated with breast can-
cer progression, we used an informatics approach [1] and
mined multiple independent microarray datasets of
breast tumor profiles for genes having significant and
reproducible associations with distant metastasis-free
survival (DMFS). JMJD6 emerged as a top candidate,
because its expression was significantly and positively
associated with decreased time to distant metastasis in
eight of the 14 breast cancer cohorts examined (Figure 1
and Additional file 1, Table S1). Furthermore, in an inte-
grated Super Cohort (SC) (n = 1,954) comprising
the majority of the individual cohorts listed in Table 1
(see Methods and Additional file 1, Table S1), high
JMJD6 expression was significantly associated with
decreased time to distant metastasis with a hazard ratio
of 1.92 (95% CI, 1.62 to 2.29; P < 0.001). Together, these
observations indicate a robust and reproducible associa-
tion between JMJD6 expression and aggressive clinical
behavior of breast cancer that may reflect an underlying
functional contribution of JMJD6 in breast cancer
progression.
JMJD6 expression in breast cancer subtypes
Breast cancers were classified based on hormone-receptor
status, estrogen receptor (ER+/-), or gene expression into
intrinsic subtypes as described by Perou et al. [23].
Because these subclasses show differential survival, we
analyzed the expression level of JMJD6 in each subtype
annotated in the Super Cohort. As shown in Figure 2A,
overall ER- tumors had slightly but significantly elevated
expression of JMJD6 (P < 0.001). The average JMJD6
expression differed across the intrinsic subtypes. JMJD6
expression was highest in Claudin-low tumors and basal
subtypes, followed by HER2, whereas in the ER+ group,
the luminal B (LumB) expressed more JMJD6 than did
luminal A (LumA) (P < 0.05) (Figure 2B). We examined
the survival outcome of JMJD6 high- and low-expresser
groups, determined by median separation across the Super
Cohort, within each subtype. Because ER- tumors had very
high levels of JMJD6 expression, further separation based
on JMJD6 levels and survival analysis bore no significance
(Table 1). In ER+ tumors, high JMJD6 expressers had
poorer outcome than low expressers (Figure 2C; P <
0.001), and this persisted on subdivision of ER+ into lumi-
nal subclasses (Figure 2D and 2E). Further, in the tamoxi-
fen-treated samples, high JMJD6 expressers had worse
outcome. However, whether JMJD6 predicts endocrine
failure must be studied further. These data are summar-
ized in Table 1. Other than total cohort median-based
separation of patients, we also examined the relation of
Lee et al. Breast Cancer Research 2012, 14:R85
http://breast-cancer-research.com/content/14/3/R85
Page 5 of 16
JMJD6 levels and prognosis by quartile assignment of
JMJD6 expression in each subtype independently. With
this method, we observed that extremely high expression
of JMJD6 (upper quartile) significantly led to worse survi-
val outcomes in luminal A and luminal B subtypes (P <
0.05) (see Additional file 3, Figure S1). Therefore, we con-
clude that JMJD6 is a marker for tumor aggressiveness
and maybe is prognostic of poor outcome in ER+ breast
cancer.
JMJD6 protein associates with high-grade and ER- tumors
To study the distribution of JMJD6 protein levels, we
immunohistochemically (IHC) stained an 81-breast
tumor tissue array by using a JMJD6-specific antibody
(Figure 3A). MCF-7-J1 OE and JMJD6 siRNA-treated
cells were used to confirm the specificity of the antibody
(see Additional file 4, Figure S2). As shown, JMJD6 was
present predominantly in the nuclei of breast tumor
cells, with increased staining evident in higher grades of
breast tumors. Univariate analysis clearly identified an
association between high JMJD6 staining, high grade,
and ER negativity (Figure 3B). Similar to the RNA-
expression data, JMJD6 protein was highly expressed in
more-aggressive and advanced tumors. However,
because of the low sample size, our analysis could not
explore whether JMJD6 correlates with outcome in
luminal tumors. Nonetheless, JMJD6 appears to be a
relevant marker in breast cancer pathogenesis.
JMJD6 increases proliferation in MCF-7 cells
Because the JMJD6 expression profile was similar to the
proliferative gene cluster, as characterized by Perou et al.
[14,24], we posited that perturbation of its levels may
affect cell proliferation (Figure 2A and 2B). We studied
JMJD6 expression in a panel of five breast cancer cell lines
(see Additional file 5, Figure S3A). With the exception of
MCF-7 cells, JMJD6 was highly expressed in breast cancer
cell lines. We used a lentiviral-based cloning system to
infect MCF-7 cells with V5-tagged JMJD6 and achieved
stable expression of JMJD6 (MCF-7 J1-OE). As a pool,
these cells showed increased proliferation (see Additional
file 6, Figure S4), and this was confirmed in individual
clones, J1-C2, J1-C3, and J1-C7 (Figure 4A). Over a period
of 5 days, MCF-7-J1-OE clones (J1-C2, J1-C3, and J1-C7)
showed higher proliferation as early as day 2 and contin-
ued to grow faster as compared with empty vector control
cells (Vec) (Figure 4A). Next we silenced JMJD6 expres-
sion in all five cell lines by using a panel of siRNAs and
assayed their proliferation. We achieved 80% to 100%
silencing of JMJD6 protein, depending on the basal, endo-
genous expression level of JMJD6 (see Additional file 5,
Figure 1 High JMJD6 mRNA expression is associated with poor survival outcome. Cox regression analysis of JMJD6 expression and distant
metastasis-free survival of patients was initially performed in 14 microarray expression datasets independently and then subsequently on a
“Super Cohort” (SC) comprising 15 Affymetrix array-based cohorts, including a subset of the 14 cohorts used initially. Hazard ratios and their 95%
confidence intervals are shown in the forest plot. Datasets are listed on the Y-axis; all platforms are from Affymetrix array series, with the
exception of NKI from Agilent. The 95% confidence intervals are indicated by the error bars, and the cohort size is shown in parentheses.
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.005.
Table 1 Hazard ratios of JMJD6 expression groups in
various subtypes of breast cancer
Subtypes Cohort size
(JMJD6 high, low)
Hazard ratio (95% CI) P value
Basal 84, 250 0.904 0.572-1.43 0.667
Claudin-Low 19, 73 1.577 0.542-4.587 0.403
Her2 98, 183 0.843 0.56-1.27 0.415
Lum A 309, 256 1.524 1.009-2.304 0.045
Lum B 116, 283 1.712 1.132-2.591 0.011
ER - 247, 154 1.067 0.742-1.536 0.725
ER+ 731, 822 1.912 1.546-2.364 < 0.001
CoxPH analysis of JMJD6 expression cohorts (high versus low separated by
median of JMJD6 expression across the Super Cohort) was performed in
annotated subtypes of breast cancer. The table shows the number of patients
used for the analysis in the high- and low-JMJD6 expression cohorts, the
hazard ratio, and its 95% confidence interval (CI) and P value generated from
the analysis in each subtype.
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Figure S3A). Four different siRNAs resulted in profound
loss of proliferation in MCF-7 and MDA MB231 cells
(Figure 4B and 4C). This decrease was not due to
increased apoptosis, because higher levels of cleaved PARP
were not evident in the JMJD6 knockdown cells (see Addi-
tional file 5, Figure S3B). Similar to MCF7 and MDA-
MB231, siRNA treatment decreased proliferation in the
remaining cell lines: BT-549, CAMA-1, and T47D (see
Additional file 5, Figure S3C). Together, these results sug-
gest that high levels of JMJD6 lead to increased cell prolif-
eration. To determine whether further induction of JMJD6
in cells with intrinsically higher JMJD6 levels shows an
additive increase in cell proliferation, we generated
MB231-J1-OE, T47D-J1-OE, and CAMA-J1-OE cells (see
Additional file 7, Figure S5). However, an increased dosage
of JMJD6 did not further augment cell growth
JMJD6 enhances scattering and motility
Our in silico analysis and IHC data showed that JMJD6 is
associated with aggressive advanced disease. We next stu-
died whether this protein could influence cell motility
and invasion by using cell-scatter, wound-healing, and
Boyden chamber assays. The motility and invasion assays
were performed within 24 hours to minimize secondary
effects of cell proliferation. For the scattering phenotype,
we used a counting system previously described by Shtut-
man et al. [19] to evaluate the degree of scattering
(Figure 5A). All three MCF-7-J1-OE clones showed an
increase in scattering as compared with Vec cells. An
increase in scattering often implies a gain in motility or
epithelial-mesenchymal transformation (EMT). There-
fore, we assayed loss of E-cadherin and gain in vimentin
as markers for EMT. Immunoblots showed that MCF-
7J1-OE clones maintained E-cad expression (see Addi-
tional file 8, Figure S6), suggesting that the scattering is
probably encouraged by motility. Indeed, in a wound-
healing assay, MCF-7-J1-OE clones closed the wound
much faster than did Vec cells (Figure 5B). Because
increased cell number due to increased proliferation can
mislead interpretation of wound-healing data; we per-
formed these assays in the presence of mitomycin C, an
inhibitor of cell division. Despite a gain in motility, we
were unable to demonstrate an increase in invasive beha-
vior in MCF-7-J1-OE cells (data not shown). However, in
MDA-MB231, a highly motile and invasive cell line,
knockdown of JMJD6 significantly attenuated both prop-
erties (Figure 5C). To negate the contribution of
decreased proliferation in this assay, we normalized these
results to the proliferation changes observed on day 2
(Figure 5C). However, the cells maintained loss in moti-
lity and invasion, showing that this property was inde-
pendent of proliferation defects. Together, these data
imply that JMJD6 is not a “driver” of cell invasion but
may augment cell movement.
Figure 2 JMJD6 expression and prognosis in intrinsic subtypes of breast cancer. Box plots of JMJD6 expression demonstrate (A) higher
JMJD6 probeset intensity (log2) in ER- tumors compared with ER+ tumors, with P < 0.001 by Mann-Whitney Rank Sum test; and (B) highest
JMJD6 probeset intensity (log2) in claudin-low and basal subtypes, followed by HER2-enriched and LumB subtypes, and lowest in LumA
subtypes. The Dunn method was used to perform pairwise multiple comparison among the subtypes. *P < 0.05 between a pair of subtypes.
Dots of boxplots (A, B) represent outliers in the 90th and 10th percentiles. Kaplan-Meier survival curves based on below-median (low) and above-
median (high) JMJD6 expression are shown for (C) ER+ patients, (D) patients of LumA subtype, (E) patients of LumB subtype, and (F) ER+,
tamoxifen-treated patients. The numbers in the parentheses equal patient numbers in each group, and the log rank P value is indicated at the
bottom left of each figure.
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JMJD6 expression inversely correlates with TGF-b2
To determine the pathways involved in JMJD6-induced
proliferation, we performed microarray analysis by using
the MCF-7-J1-OE clones and JMJD6 siRNA-treated MCF-
7 and MDA-MB231 cells. We selected 2,216 overlapping
probe sets that were commonly and appropriately regu-
lated in all three settings: MCF-7-J1-OE, MCF-7 siRNA,
and MDA-MB231 siRNA (see Additional file 9, Table S3).
Figure 3 Nuclear JMJD6 protein expression is associated with high-grade breast tumors. Representative breast cancer cores from tissue
microarray that were stained with JMJD6 antibody are shown. Low-grade (left panel), intermediate-grade (middle panel), and high-grade breast
tumors (right panel) are shown (magnification, ×60). The table in the figure shows univariate analysis of JMJD6 and clinical parameters.
Figure 4 Expression of JMJD6 enhances proliferation. (A) WST-1 assays using MCF-7-J1-OE clones (J1-C2, J1-C3, and J1-C7) showed increased
proliferation over vector control cells (Vec). SiRNA-mediated knockdown of JMJD6 and resultant decrease in proliferation is shown in (B) MCF-7
and MDA-MB231. Four individual siRNAs (A, B, C, and D) were used: Sc, scrambled siRNA; and NT, non-transfected cells served as control. Inset in
each panel shows protein levels of JMJD6 after siRNA transfection. b-actin immunoblots show equal protein loading in all lanes.
Lee et al. Breast Cancer Research 2012, 14:R85
http://breast-cancer-research.com/content/14/3/R85
Page 8 of 16
Clusters of genes regulated in the opposite directions in
JMJD6 overexpression and JMJD6 knockdown were
denoted JMJD6-induced and JMJD6-repressed gene sets,
respectively (Figure 6). We analyzed these two gene sets
with Ingenuity Pathway Analysis [20]. In accordance with
our cell-based assays, in the JMJD6-induced gene set, the
top enriched functions were cell-cycle and DNA replica-
tion, followed by cellular assembly and cellular movement
(Figure 6; see Additional file 10, Table S4). In the JMJD6-
repressed subset, a large number of genes were related to
cancer function (120) (Figure 6). Among the associated
gene functions, we observed a significant downregulation
of TGF-b isoforms, the classic cell-cycle inhibitors [25-27]
(see Additional file 10, Table S4), which was further con-
firmed by using quantitative RT-PCR. Loss of JMJD6
increased TGF-b1 and TGF-b2 expression, whereas TGF-
b3 was unaffected in both MCF-7 and MDA-MB231 (Fig-
ure 7A and 7B). Protein analysis suggested that both
JMJD6 siRNAs induced a high level of TGF-b2 secretion
in the two cell lines (Figure 7C). In contrast, in MCF-7-J1-
Figure 5 JMJD6 promotes motility in breast cancer cell lines. (A) Scatter phenotype was scored based on three levels of scattering
(compact, loose, scatter) (upper panel). Bar graphs represent quantification of scattering of colonies by using the Student t test (lower panel).
MCF-7 J1 OE clones had a higher percentage of scattered or loosely scattered clones than did the control Vec cells. (B) Wound-healing assay
showed that MCF-7 J1 clones displayed higher motility in comparison to Vec (upper panel); quantification of wound closure as a ratio to the Vec
is shown in the lower panel. *P ≤ 0.05 by Student t test in comparison to Vec control. (C) Boyden-chamber assay results of MDA-MB231 cells
with JMJD6 siRNA-mediated knockdown were normalized to fold change in proliferation at Day 2 of WST-1 measurement. Two of three siRNA
knockdowns of JMJD6 showed significantly decreased motility, and all siRNA knockdowns of JMJD6 showed decreased invasiveness. *P ≤ 0.05;
**P ≤ 0.001 by Student’s t- test when compared with Sc siRNA.
Lee et al. Breast Cancer Research 2012, 14:R85
http://breast-cancer-research.com/content/14/3/R85
Page 9 of 16
OE cells, a significant decrease in TGF-b2 mRNA and pro-
tein expression was observed (Figure 7D and 7E). At the
protein level, we failed to detect changes in TGF-b1 and
TGF-b3, although both isoforms were expressed (data not
shown). Therefore, of the three isoforms, TGF-b2 prob-
ably was more engaged in JMJD6-mediated cellular
proliferation.
JMJD6 possibly engages multiple pathways to increase
cell proliferation
JMJD6 suppressed TGF-b2 expression and cell prolifera-
tion in both MCF-7 and MDA-MB 231 cells. However,
TGF-b2 mediates cell-cycle arrest only in MCF-7 cells,
but not in MDA-MB 231, T47D, and CAMA-1 cells
[28-30]. Therefore, TGF-b2 may not be the mediator of
Figure 6 IPA analysis of JMJD6-regulated genes showed enrichment in cell-cycle function. (A) The heatmap (top panel) shows that
hierarchic clustering of the genes changed after siRNA knockdown and overexpression of JMJD6. The sample labels are on the top of the heat
map. Two clusters representing JMJD6-induced and JMJD6-repressed genes were selected (middle heat-map panel) and subjected to IPA
analysis. (B) Table shows a list of the top 10 functions that are enriched in cells with altered levels of JMJD6.
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cell-cycle arrest in the latter three cell lines, even though
MDA-MB231s are responsive to TGF-b in terms of
SMAD phosphorylation and TGF-b-mediated transcrip-
tional changes [31]. To test the functionality of TGF-
b2, we did the following: (a) assessed Smad2/3 phos-
phorylation levels in both cells, (b) neutralized TGF-b2
by using a TGF-b type I receptor inhibitor SB431542
and assayed Smad phosphorylation and cell proliferation
in the absence of JMJD6, and (c) treated MCF-7-J1OE
cells with recombinant TGF- b2.
By treatment of recombinant TGF-b2 on MCF-7 and
MDA-MB231, we confirmed that both cell lines
responded with increased SMAD2 phosphorylation,
which suggests intact TGF-b receptor signaling (Figure
8; see Additional file 11, Figure S7A). Similarly, an
increase in SMAD2 and SMAD3 phosphorylation with
JMJD6 siRNA treatment was seen in both MCF-7 and
MDA-MB231, as opposed to a decrease observed in the
MCF-7 J1 OE clones (Figure 8). Interestingly, basal
SMAD levels themselves were affected, which parallels
the transcript-level change detected in our expression
array (Figure 6). When we inhibited SMAD phosphory-
lation by using an Alk-5 receptor inhibitor (SB431542),
we observed a significantly higher rescue of proliferation
in MCF-7 JMJD6 knockdown cells (Figure 9A and 9B).
Because MDA-MB 231 cells are refractory to TGF-b2-
mediated cell-cycle inhibition, SB431542 should have no
effect on MDA-MB231 growth suppression. Accord-
ingly, the suppressed proliferation could not be rescued
by the Alk-5 receptor inhibitor treatment in this cell
type (see Additional file 11, Figure S7).
Last, treatment of MCF-7 J1-OE cells with recombi-
nant TGF-b2 repressed proliferation in both Vec and
J1-OE cells, suggesting that MCF-7 retained sensitivity
to TGF-b2-mediated growth regulation despite increased
JMJD6 levels (Figure 9C). Therefore, JMJD6 did not
confer unresponsiveness to this growth factor, but prob-
ably mediated its effect via repression of gene expres-
sion. Together these data suggest that in MCF-7 cells,
JMJD6 mediates cell-cycle regulation, in part by sup-
pressing TGF-b2.
Secretion of TGF-b2 cannot explain the growth arrest
in JMJD6 siRNA-treated MDA MB 231 cells. Scanning
of microarray data revealed that JMJD6 changed the
levels of G1 cyclins: cyclins E1, E2, and D at the RNA
level. In MDA MB 231 cells, we confirmed a loss in
Figure 7 JMJD6 represses TGF-b2 expression. RT-qPCR assays of TGF-bs after JMJD6 siRNA-mediated knockdown are shown in (A) MCF-7 and
(B) MDA-MB231. Consistently, TGF-b2 and TGF-b1 mRNA levels were upregulated on JMJD6 knockdown. (C) Immunoblots showed that the
amount of secreted TGF-b2 protein in conditioned media was higher after JMJD6 siRNA-mediated knockdown in MCF-7 and MDA-MB231. (D)
RT-qPCR assay showed that MCF7 J1 OE clones had a lower level of TGF-b1 and TGF-b2 transcripts than did the Vec cells. (E) Western blot
showed a dramatic decrease in secreted TGF-b2 protein, in the MCF-7 J1 clones, as compared with the Vec cells. NS, a Ponceau-stained blot of
the conditioned media to demonstrate protein loading. Student’s t- test was performed by using scrambled siRNA versus JMJD6 siRNA and Vec
cells versus MCF-7J1 clones. *P ≤ 0.05; **P ≤ 0.005.
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cyclin E2 protein expression but not E1 or cyclin D in
JMJD6 siRNA-containing cells (Figure 10). Interestingly,
cyclin E1/E2 was decreased in MCF-7 JMJD6 siRNA-
treated cells and induced in MCF-7-J1 OE cells and
(Figure 10). Together these data indicate that in both
cells, JMJD6 mediated suppression of TGF-b2. In MCF-
7 cells, the proliferation is controlled by both TGF-b2
and cyclin E regulation, but in MDA 231 cells, the
Figure 8 JMJD6 expression affects SMAD phosphorylation. Immunoblots show that the levels of total SMAD2/3, phosphorylated SMAD2,
and phosphorylated SMAD3 are decreased in MCF-7 J1-OE clones and increased in JMJD6 siRNA-mediated knockdown in MCF-7 and MDA-
MB231. The numbers next to the SMAD2P/3P denote the expected sites of phosphorylation detected by the antibodies. NS, nonspecific bands
from the blots, which indicate equal loading of the protein lysates.
Figure 9 TGF-b2 inhibits proliferation in MCF-7. (A) Immunoblots showed that treatment of MCF-7 by recombinant human (rh) TGF-b2 (5 ng/ml)
resulted in enhanced Smad2 phosphorylation, which could be effectively nullified by SB431542. (B) Treatment of JMJD6 siRNA-transfected MCF-7 cells
with SB431542 (10 μM) resulted in rescue of the proliferation defect. Ratio of OD at Day 3 to Day 1 in JMJD6 knockdown cells was normalized to the
scrambled siRNA control. *P ≤ 0.05; **P ≤ 0.005 between DMSO and SB431542 treatments. (C) Treatment of MCF-7 J1-OE and Vec cells with rhTGF-b2
resulted in decreased proliferation, as measured by WST-1 assay. **P ≤ 0.001 between BSA and rhTGF-b2 treatments.
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cyclin E regulation may contribute to this phenotype,
rather than TGF-b2 signaling. Other pathways that
operate in MDA-MB 231 cells must be explored further.
Clinical data for JMJD6 and TGF-b2
Finally, by using expression data from the clinical
cohorts, we observed a marginal but significant inverse
correlation of JMJD6 with TGF-b2 (Pearson correlation
value, -0.118; P value = 9.13 × 10-8) (Figure 11). This
suggests that this TGF-b2 mechanism observed in vitro
could be extrapolated to patient data and that the MCF-
7-OE cells could serve as a model system to explore the
pathways involved in further detail.
Discussion
Through microarray informatics, we identified JMJD6 as
a candidate oncogene associated with poor patient prog-
nosis. Consistent with its potential as a marker of breast
cancer aggressiveness, JMJD6 was expressed at highest
levels in ER-, basal, claudin-low, HER2-enriched, and
Luminal B tumor subtypes, which are known to be clini-
cally associated with poor patient outcomes. Most
important, in the less-aggressive ER+ subtypes (for
example, Luminal A), high levels of JMJD6 could predict
poor outcome and possibly resistance to tamoxifen
monotherapy. Protein analysis by using tissue microar-
ray confirmed that high JMJD6 expression is consistently
associated with ER- disease, higher grade, and advanced
stage. These data demonstrate for the first time that
JMJD6 is a relevant prognostic biomarker in breast
cancer.
By phenotypic and functional analysis, we found that
JMJD6 induced an increase in cell scattering and
increased the rate of wound closure in MCF-7 cells, but
did not confer an invasive phenotype. In invasive cells
like MDA-MB231 and BT-549 with high expression of
JMJD6, siRNA-mediated suppression led to loss of both
motility and invasiveness properties. Because forced
JMJD6 expression did not confer invasiveness, this
apparent loss of invasiveness most likely follows a loss
in motility. Nonetheless, JMJD6 may have a critical role
in epithelial cell movement, and we showed that this
property is not restricted to endothelial cells [7]. How-
ever, this appears to be a minor function of JMJD6,
because its exogenous expression did not induce epithe-
lial-to-mesenchymal transition (EMT) (that is, we did
not observe a loss or gain in E-cadherin or vimentin
expression, respectively, in MCF-7 J1-OE cells).
The most prominent effect of JMJD6 perturbation was
on cell proliferation. SiRNA-mediated attenuation of
JMJD6 in multiple breast cancer cells led to a decrease
in cell proliferation without activation of cellular apop-
tosis, whereas forced expression in MCF-7 resulted in a
massive increase in cell proliferation. This finding is
consistent with the observation that JMJD6-knockout
mice are small and show growth retardation [3]. The
role of JMJD6 in proliferation is further substantiated by
our microarray analysis, which revealed that modulation
of JMJD6 expression significantly affected the expression
levels of a number of cell cycle-associated genes (see
Additional file 10, Table S4). Although JMJD6 is thought
to mediate splicing by physical interaction with U2AF65,
we obtained very little evidence for alternate transcripts
in both cell lines. Conversely, we documented a large
number of transcriptional changes in J1-OE clones and
JMJD6 knockdowns.
The TGF-b pathway, particularly TGF-b2, was down-
regulated when JMJD6 was overexpressed and induced
when JMJD6 was depleted. We validated the inverse
relation between JMJD6 and TGF-b2 at both RNA and
protein levels in these cellular systems. We extended
this observation to clinical samples and observed an
inverse correlation between JMJD6 and TGF-b2 in our
breast cancer cohorts. Such antagonistic roles of JMJD6
and TGF-b2 have a precedent in eye development. One
of the distinctive developmental defects of JMJD6-
Figure 10 Decrease of cyclin E2 protein level in JMJD6
knockdown. Western blot detection of G1 cell-cycle cyclins is
shown. A decrease in cyclin E2 (CCNE2) level with decrease in
JMJD6 levels was evident in MCF-7 and MDA-MB231. Cyclin E1
(CCNE1) and cyclin D1 (CCND1) displayed an inconsistent change
on JMJD6 siRNA transfection in both MCF-7 and MDA-MB231 cells.
Figure 11 Clinical association of JMJD6 with TGF-b2. Pearson
correlation of clinical expression of JMJD6 with TGF-b2 suggests a
negative correlation with TGF-b2 (P = 9.13 × 10-8). Scatterplot shows
the normalized JMJD6 expression of each patient sample with the
corresponding normalized TGF-b2 expression in the clinical dataset
of 2,034 breast cancer patients.
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knockout mice is the thinning of the retinal layer [3].
Coincidentally, the knockout of TGF-b2 results in the
hyperplasia of the neuroblastic layer of the retina [32].
These data suggest that JMJD6 and TGF-b2 may be
functionally linked in cell-cycle regulation and in
development.
Canonically, TGF-bs are known to exert antiprolifera-
tive effects by upregulating cyclin-dependent kinase
inhibitors, p15 and p21, and/or downregulation of
CDK2 and cyclin E activity [26,27,33-35]. In both MCF-
7 and MDA-MB 231 transfected with JMJD6 siRNA, we
observed suppression of cyclin E expression, and an
increase in cyclin E was evident when JMJD6 was over-
expressed in MCF-7 cells. Therefore, in both cell lines,
JMJD6 may exert a proliferative effect through a direct
increase in cyclin E protein levels, or this increase may
be a consequence of JMJD6-mediated suppression of
TGF-b2. In both MCF-7 and MDA-MB231, the down-
stream effectors, Smads, were phosphorylated on JMJD6
siRNA-mediated secretion of TGF-b2. Specifically, in
MCF-7, inhibition of TGF-b activity by using a TGF-b
type I receptor (Alk5) inhibitor resulted in the loss of
Smad phosphorylation, rescue of arrested cells, and con-
tinuation of proliferation (Figure 9). The Alk5 inhibitor
did not reverse cell-cycle arrest in MDA-MB 231 cells
because they are refractory to the antiproliferative effect
of TGF-b, suggesting that the JMJD6-cyclin E axis may
function independent of TGF-b2 in these cells. Intrigu-
ingly, cyclin E is associated with poor prognosis, chro-
mosomal instability, and trastuzumab resistance,
suggesting that the long-term dysregulation of cell-cycle
mediators by JMJD6 may affect more than just prolifera-
tion [36-38].
Our initial microarray analysis selected genes that
were commonly regulated by JMJD6 in both MCF-7 and
MDA-MB 231 cells. To elucidate further the mechan-
isms behind JMJD6 siRNA-mediated growth suppression
in MDA-MB 231 cells, we reanalyzed gene-expression
changes unique to MDA-MB 231 cells alone. We found
1,864 probesets, with significant enrichment of genes
involved in cellular death, growth and proliferation, and
cell movement (P < 0.01; see Additional file 12, Figure
S8). Close inspection showed at least 28 individual
genes in this proliferation gene cassette (see Additional
file 13, Table S5); however, no connectivity or compel-
ling pathway emerged that could be investigated further.
Conclusion
In summary, our data indicate that JMJD6 has conserved
functions and often affects similar pathways in a congru-
ent manner across multiple cell types and at a gene-
expression and phenotypic level. JMJD6 has ability to
promote cancer cell proliferation and motility, which in
turn may augment cancer virulence in vivo. In the clinic,
JMJD6 associates with advanced grade, an aggressive
phenotype, and serves as a marker of poor prognosis in
breast cancer. We propose that JMJD6 staining (with
IHC) may serve a dual purpose in the clinic: to predict
poor outcome in patients, particularly in the ER+ sub-
type, and to identify a patient subgroup wherein specific
inhibitors of JMJD6 may facilitate the pathologic down-
staging of tumors in the neoadjuvant setting.
Additional material
Additional file 1: Table S1. QPCR Primers. QPCR primer sequences
used in the RT-PCR.
Additional file 2: Table S2. Microarray datasets. List of clinical
microarray datasets used in the survival analysis of JMJD6 and their
general information, including database source and literature references.
Additional file 3: Figure S1. Upper-quartile expression of JMJD6 is
associated with poor survival in LumA and LumB subtypes. Kaplan-
Meier survival curves were generated based on quartile ranking of JMJD6
expression within the individual subtype. Representative images are
shown for (A) LumA subtype and (B) LumB subtype. *Log rank P < 0.05;
#log rank P < 0.001 between two quartile expression groups within the
subtype.
Additional file 4: Figure S2. Standardization of JMJD6
immunohistochemistry. IHC for JMJD6 was performed on wild-type (left
panel), JMJD6 siRNA-mediated knockdown (middle panel), and JMJD6-
overexpressing (right panel) MCF-7 cells. As shown in the figure, wild-
type and JMJD6 siRNA cells showed low to negligible amounts of
immunoreactivity, whereas expression of JMJD6 was the highest in
MCF7-J1-OE cells.
Additional file 5: Figure S3. Protein expression and knockdown of
JMJD6 in other cell lines. (A) Western blot of different breast cancer
cell lines suggests that JMJD6 protein expression was low in MCF-7,
whereas MDA-MB231, T47D, CAMA-1, and BT-549 cells harbored
substantial amounts of JMJD6 protein. (B) Level of apoptosis in cells
transfected with JMJD6 siRNA was determined by using a PARP-cleavage
assay. Bar chart shows that the percentage of cells with cleaved PARP
was similar in both JMJD6 siRNA and scrambled siRNA-transfected MCF-7
cells. (C) Decreased proliferation was observed in BT-549, CAMA-1, and
T47D when JMJD6 was knocked down by three individual JMJD6-specific
siRNAs after 4 days of plating, as compared with the scrambled siRNA
control (Sc siRNA); P ≤ 0.005. Error bars represent standard deviation.
Additional file 6: Figure S4. Pooled population of MCF-7 J1-OE cells
showed increased proliferation and decreased TGF-b2 levels. (A)
WST-1 assay using MCF-7 J1-OE pooled population before clonal
selection showed increased proliferation over vector control cells (Vec).
(B) Immunoblots of conditioned media showed decreased levels of
secreted TGF-b2 in MCF-7 J1-OE pooled population as compared with
Vec. NS, nonspecific bands from the same TGF-b2 antibody blot to
indicate even total protein loading.
Additional file 7: Figure S5. Overexpression of JMJD6 in CAMA,
T47D, and MDA-MB231 had no effect on proliferation. Figures (top
panel) show Western blot for V5-tagged JMJD6 clones expressed in (A)
CAMA, (B) T47D, and (C) MDA-MB231, respectively, and b-actin as an
internal control for loading. A through C (bottom) show that stable
JMJD6 overexpression clones did not display increased proliferation as
compared with the Vec control.
Additional file 8: Figure S6. MCF-7 J1-OE cells did not show
changes in E-cadherin and vimentin levels. Immunoblots showed that
the expression of E-cadherin is similar in the MCF-7 J1-OE cells and Vec
cells. Vimentin remained unexpressed in MCF-7 J1-OE cells. MDA-MB231
was used as a positive control for the vimentin antibody.
Additional file 9: Table S3. Microarray analysis. List of genes that
were differentially expressed by microarray analysis of MCF-7 J1-OE
clones and JMJD6 siRNA knockdown cells.
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Additional file 10: Table S4. JMJD6 and gene function. Top ten
functions enriched in JMJD6-induced and JMJD6-repressed gene sets by
IPA functional analysis and the list of genes in each function.
Additional file 11: Figure S7. SB431542 does not rescue JMJD6
siRNA-mediated loss of proliferation in MDA-MB231. (A)
Immunoblots showed that treatment of rhTGF-b2 in MDA-MB231
resulted in enhanced SMAD2 phosphorylation, which could be nullified
by SB431542 treatment. (B) JMJD6 siRNA-mediated decreased
proliferation of MDA-MB231 could not be rescued by SB431542 (10 μM)
treatment, as assessed with WST-1 OD measurement.
Additional file 12: Figure S8. Functional annotation of differentially
expressed genes unique to MDA-MB 231 cells transfected with
JMJD6 siRNA. Bar chart shows IPA functional annotation analysis of
differentially expressed genes in MDA-MB231 JMJD6 siRNA-mediated
knockdown showed significant enrichment of genes involved in cellular
death, growth, and movement. Log P-value on the X-axis is Fisher Exact
test on the overlap of our gene list and the functional category
(Additional File 13, Table S5).
Additional file 13: Table S5. “Proliferation” genes differentially
expressed in MDA-MB231. List of genes found in subcategories under
the functional annotation for cellular growth and proliferation that were
significantly enriched (P < 0.05). The P value is from the Fisher Exact test
for the overlap of our dataset and the function. The predicted activation
state is stated for significant direction of change (Z score, ≤-2).
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